Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

Rhea-AI Summary

Achilles Therapeutics plc (ACHL) will be presenting at the 10th Annual Immuno-Oncology 360 Conference to discuss precision T cell therapies targeting clonal neoantigens for solid tumors. The presentation will be led by Sergio Quezada, PhD, the Chief Scientific Officer, and will take place in New York on February 29, 2024.

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference:

10th Annual Immuno-Oncology 360 Conference (IO360)
Speaker: Sergio Quezada, PhD, Chief Scientific Officer
Presentation: Targeting Clonal Neoantigens with Precision Cell Therapies
Location: New York Marriott at The Brooklyn Bridge, Brooklyn NY
Date: February 29, 2024
Time: 10:30am ET

For more information about IO360, please visit https://io360summit.com.

About Achilles Therapeutics

Achilles is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Investors:
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com

Media:
ICR Consilium
Sukaina Virji, Tracy Cheung, Emmalee Hoppe
+44 (0) 203 709 5000
achillestx@consilium-comms.com

FAQ

What is the ticker symbol for Achilles Therapeutics plc?

The ticker symbol for Achilles Therapeutics plc is ACHL.

What is the focus of the presentation at the 10th Annual Immuno-Oncology 360 Conference?

The presentation will focus on targeting clonal neoantigens with precision cell therapies for solid tumors.

Who will be leading the presentation at the conference?

Sergio Quezada, PhD, the Chief Scientific Officer, will be leading the presentation.

When and where will the presentation take place?

The presentation will take place at the New York Marriott at The Brooklyn Bridge in Brooklyn, NY, on February 29, 2024, at 10:30am ET.